Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TLX
TLX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TLX News
Telix Completes Patient Enrollment for TLX101-Tx Clinical Trial
4d ago
Newsfilter
Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments
May 15 2026
Newsfilter
Telix Publishes ZIRCON Trial Data Analysis Indicating High Predictive Value of TLX250-Px
May 04 2026
Newsfilter
Telix Pharmaceuticals Presents TLX597-Tx Dosimetry Data from Phase 2 Trial
May 01 2026
NASDAQ.COM
Telix Pharmaceuticals' European MAA for TLX101-Px Accepted for Review
May 01 2026
Newsfilter
Telix's Marketing Application Accepted, Advancing Brain Tumor Imaging
Apr 30 2026
Newsfilter
Telix Reports Clinical Data for TLX597-Tx
Apr 29 2026
Newsfilter
Telix Webinar on PSMA-Targeted Prostate Cancer Therapy
Apr 27 2026
Newsfilter
Telix Pharmaceuticals to Present Key Study Data at ASCO Meeting
Apr 21 2026
Newsfilter
Telix Pharmaceuticals Enters Phase 3 Trial for Brain Cancer Treatment
Apr 19 2026
Yahoo Finance
Telix Pharmaceuticals Doses First Patient in Phase 3 Trial for Glioblastoma Treatment
Apr 15 2026
NASDAQ.COM
Telix's TLX101-Tx Enters Phase 3 Clinical Trial for Glioblastoma
Apr 14 2026
Newsfilter
Telix Successfully Prices $600 Million Convertible Notes Offering
Apr 14 2026
Newsfilter
Telix Doses First Patient in Phase 3 IPAX BrIGHT Trial for Recurrent Glioblastoma
Apr 14 2026
Yahoo Finance
Telix Successfully Prices $600 Million Convertible Notes Offering
Apr 14 2026
PRnewswire
Telix Launches $550 Million Convertible Notes Offering
Apr 14 2026
PRnewswire
Show More News
